← All trials
NCT05046041
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2020
- Primary completion
- Aug 31, 2021
- Completion date
- Aug 31, 2021
- First posted
- Sep 16, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gynuity Health ProjectsLead sponsor
- Gynuity Health ProjectsOverall official - principal investigator
- Bharatpur Eye Hospital, NepalOverall official - principal investigator
- Bharatpur Eye Hospital, NepalCollaborator
- Government of NepalCollaborator
- CREHPAOverall official - principal investigator
- Lumbini Provincial HospitalOverall official - principal investigator
- Lumbini Provincial HospitalCollaborator
- KIST Medical CollegeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.